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Dear Sir:
Previous clinical trials to prevent post-stroke cognitive impair-
ment, such as Prevention Regimen for Effectively Avoiding 
Second Strokes (PRoFESS) and Secondary Prevention of Small 
Subcortical Strokes (SPS3), failed to show clinically meaningful 
results.1,2 There is an evidence that cilostazol, a phosphodies-
terase-3 inhibitor, could suppress cognitive decline in patients 
with dementia,3 and decrease amyloid beta accumulation.4 
Probucol, a cholesteryl ester transfer protein activator with lip-
id-lowering and anti-oxidative effects, has a beneficial effect 
on cognition by inhibiting amyloid beta-induced hippocampal 
synaptic impairment.5 Thus, we aimed to determine the effica-
cy of cilostazol and probucol for preventing poststroke cogni-
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tive decline in patients with multiple cerebral microbleeds 
(CMBs) or a history of prior intracerebral hemorrhage (ICH); a 
population that is expected to have a high risk for future cog-
nitive decline. 
PreventIon of CArdiovascular events in iSchemic Stroke pa-
tients with high risk of cerebral hemOrrhage for reducing COG-
nitive decline (PICASSO-COG) is a predetermined substudy of 
the PICASSO trial, which is a randomized double-blinded pla-
cebo-controlled trial with a 2×2 factorial design: cilostazol 
versus aspirin, and probucol versus no probucol.6 The design 
and analysis plan have been previously reported.7 The key in-
clusion criteria were non-cardioembolic ischemic stroke or 
transient ischemia attack and previous ICH or multiple CMBs 
on gradient echo imaging. Cognitive function was assessed us-
ing the Mini-Mental State Examination (MMSE) and the Mon-
treal Cognitive Assessment (MoCA) at randomization and at 4, 
13, 25, 37, and 49 months after randomization. The cognitive 
function at the second visit (4 months after randomization) in 
patients who were randomized within 3 months after stroke 
was set as the baseline function, while the cognitive function 
at the first visit (1 month after enrollment) was set as the 
baseline for those randomized beyond 90 days after stroke. The 
baseline cognitive assessment was therefore conducted be-
tween 4 and 7 months after stroke onset in all participants eli-
gible for the PICASSO-COG substudy. The primary outcome was 
a change in MMSE score, and a restricted maximum likelihood-
based mixed effects model with repeated measurements was 
used. The efficacy of each treatment was analyzed separately 
because the interaction effect between the antiplatelets and 


















































































































































































Figure 1. Mean changes in cognitive scores from baseline to each follow-up in (A, B) cilostazol vs. aspirin and (C, D) probucol vs. no probucol groups. (A, C) 
Mini-Mental State Examination (MMSE) and (B, D) Montreal Cognitive Assessment (MoCA).
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tion on the analyses, including sensitivity and subgroup analy-
ses, are presented in the Supplementary methods. 
As shown in Supplementary Figure 1, among 1,382 subjects, 
1,240 completed cognitive evaluations at randomization and 
892 subjects (877 for the MoCA) were finally included (Supple-
mentary Table 1).7 The baseline characteristics were not signifi-
cantly different between the treatment groups, except the pro-
portion of those with baseline MMSE ≤24 (Supplementary Ta-
ble 2).1 Cilostazol did not show any significant differences in 
preventing cognitive decline in comparison with aspirin (Figure 
1 and Supplementary Table 3). In the subgroup analysis ac-
cording to the baseline MMSE score, the decrease in the MMSE 
score in the aspirin group of those with baseline MMSE ≤24 
was more pronounced than that in the cilostazol group al-
though the treatment effect was not significant (Supplemen-
tary Table 4). In the propensity score-matched subsets consid-
ering the baseline differences in the proportions of those with 
baseline MMSE ≤24, the cilostazol group showed a favorable 
outcome in those with mild to moderate white matter hyperin-
tensities (WMHs) (Supplementary Table 5). Otherwise, no sig-
nificant results were found in the subgroups and sensitivity 
analysis. Probucol treatment did not show any beneficial effect 
in the primary outcome using the MMSE. When analyzed ac-
cording to the MoCA scores, probucol showed a favorable ef-
fect in preventing cognitive decline compared with the no pro-
bucol group (Supplementary Table 3). This effect was also ob-
served in the subgroups without diabetes mellitus, with con-
comitant lipid-lowering agents, with baseline MMSE >24, and 
without severe WMH (Supplementary Table 4). 
Longitudinal cognitive profiles of the study population might 
explain why this trial failed to prove the hypothesis. The demo-
graphics of the study subjects were comparable to those of the 
SPS3 trial.2 However, 69.3% of the PICASSO-COG subjects had 
moderate or severe WMH, while half of the subjects in the 
SPS3 had none or mild WMH. In this distinctive population, the 
magnitude of observed cognitive change was smaller than 
what we had expected.7 There are several reasons to consider. 
It has been reported that cognitive decline in patients with 
moderate to severe WMH was mainly observed in processing 
speed and executive function.8 In the SPS3 trial conducted in 
patients with lacunar infarction, verbal fluency was mainly im-
paired in addition to episodic memory.9 Memory dysfunction 
has also been reported to be affected by actually mediating 
executive dysfunction.8 Therefore, the MMSE was not sensitive 
enough to capture these long-term cognitive changes. The 
MoCA has been reported to be more sensitive to the stroke 
population than the MMSE; however, the MoCA total score 
seems inadequate to quantify changes over a 2-year study pe-
riod. For subsequent clinical trials, neuropsychological tests 
that more sensitively assess changes over time in the target 
population, such as fluency, trail-making, and the Stroop test 
should be adopted. In another aspect, the active risk factor 
control in the trial setting might prevent the cognitive deterio-
ration of study subjects, including the control group, and made 
it difficult to verify the effectiveness of the trial drug. This can 
be conceived from the findings from the previous trials for vas-
cular cognitive impairment, which showed stable cognitive 
trajectories in placebo arms.10 Lastly, it is possible that the het-
erogeneity of WMH might have been affected.11 The theoreti-
cally hypothesized cognitive decline might not be actually ob-
served in patients with WMH of causes other than ischemic 
origin. However, since the subjects of this trial had ischemic 
stroke based on the inclusion criteria and had preceding ICH/
multiple CMBs, the proportion of these patients is not expected 
to be high. 
We predetermined the time window of baseline cognitive 
evaluation between 4 and 7 months after entry event to mini-
mize the effects of acute stroke on cognitive function.12 The 
intervals between index-stroke and baseline evaluations were 
1 month in the PRoFESS trial and 74 to 76 days in the SPS3 
trial.1,2 If we were to include the spontaneous cognitive recov-
ery after stroke in our analysis, the effects of the study medi-
cation could be exaggerated or underestimated. 
As a limitation, the current study population did not seem to 
fulfill the criteria of reliable cognitive decline, and the trial 
needed much longer follow-up to show a significant change in 
the MMSE score.7 In addition, a treatment effect could have 
occurred between the index-stroke and the baseline assess-
ment. Since we limited our analysis to those who underwent 
baseline evaluations for 4 to 7 months after index-stroke, we 
could not address this possibility in our analysis. 
To the best of our knowledge, this is the first clinical trial 
comparing the efficacy of aspirin, cilostazol, and probucol in 
preventing poststroke cognitive decline. Cilostazol and probu-
col did not show any significant differences compared to aspi-
rin and no probucol. However, when patients were assessed by 
the MoCA, probucol reduced cognitive decline after stroke. 
Supplementary materials
Supplementary materials related to this article can be found 
online at https://doi.org/10.5853/jos.2020.03650.
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Supplementary methods
The PreventIon of CArdiovascular events in iSchemic Stroke 
patients with high risk of cerebral hemOrrhage for reducing 
COGnitive decline (PICASSO-COG) substudy was conducted 
only in South Korea (59 centers) because the cognitive assess-
ment tools had not been validated by cross-cultural studies in 
each language. 
 The primary outcome was the change in Mini-Mental State 
Examination (MMSE) score over time from baseline in an in-
tention-to-treat population. A restricted maximum likelihood-
based mixed effects model with repeated measurements 
(MMRM) was used to compare cognitive changes over time 
between groups. The model included the fixed categorical ef-
fects of treatment group and sex as well as fixed continuous 
covariates of the patient’s age, duration of education, number 
of visits, baseline cognitive scores, and the National Institutes 
of Health Stroke Scale (NIHSS) score. The effect of the study 
sites was adjusted as a random factor in the model. An un-
structured covariance structure, common to the treatments, 
was used to model the within-subject correlation. Although 
this study had a 2×2 factorial design, the efficacy of each 
treatment was analyzed separately because the interaction ef-
fect between the antiplatelets and lipid-lowering treatment 
was not significant. 
As cognitive impairment is an independent risk factor for at-
trition in a longitudinal study, we performed sensitivity analysis 
to examine its influence on cognitive outcome. Sensitivity 
analyses included the following: (1) a restricted maximum like-
lihood-based MMRM analysis with further adjustment for the 
participant’s drop-out status during the trial period as well as 
treatment status at the previous visit, which is defined as the 
patient missing the cognitive evaluation in the scheduled visit 
before the current visit, in the model; (2) MMRM analyses of 
participants’ cognitive evaluation at baseline and follow-up 
visits at 13, 25, 37, and 49 months; (3) MMRM analyses of 
participants who completed all scheduled visits during the fol-
lowing periods: baseline to 13 months, baseline to 25 months, 
baseline to 37 months, and baseline to 49 months; and (4) 
MMRM analyses of participants with ischemic stroke as an en-
try event excluding transient ischemic attack. 
The primary outcome between the comparative arms was 
compared for the following subgroups: diabetes versus non-di-
abetes, mild to moderate (Fazekas grade 0–2) versus severe 
(Fazekas grade 3) white matter hyperintensities on magnetic 
resonance imaging, baseline MMSE ≤24 versus >24, and con-
comitant use of statin versus non-use. The same analyses as 
performed in the sensitivity and subgroup analyses were re-
conducted in the propensity score matched subsets, which 
were constructed using the variables of subject age, sex, edu-
cational years, baseline cognitive score, and baseline NIHSS 
score to overcome the differences between the treatment 
groups arising from non-random missing in this substudy.
The longitudinal change in MoCA was also evaluated using 
the same statistical methods. A two-sided P-value of 0.05 was 
used to indicate statistical significance. All statistical analyses 
were performed using SAS version 9.3 (SAS Institute, Cary, NC, 
USA). 
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Supplementary Table 1. Baseline characteristics of the included and excluded subjects
Characteristic














Age (yr) 65.8±10.8 68.3±10.0 0.01 64.9±10.8 68.2±10.5 <0.01 64.8±10.8 68.3±10.4 <0.01
Female sex 480 (38.7) 53 (37.3) 0.75 327 (36.7) 153 (44.0) 0.02 318 (36.3) 162 (44.6) 0.01
Education (yr) 9 (6–12) 9 (6–12) 0.41 9 (6–12) 6 (5–12) <0.01 9 (6–12) 6 (5–12) <0.01
Hypertension 1,091 (88.0) 133 (93.7) 0.04 796 (89.2) 295 (84.8) 0.03 783 (89.3) 308 (84.9) 0.03
Diabetes 389 (31.4) 53 (37.3) 0.15 276 (30.9) 113 (32.5) 0.60 271 (30.9) 118 (32.5) 0.58
Hyperlipidemia 511 (41.2) 54 (38.0) 0.47 373 (41.8) 138 (40.0) 0.49 369 (42.1) 142 (39.1) 0.34
   Use of lipid-lowering agent* 969 (78.2) 85 (59.9) <0.01 695 (77.9) 274 (78.7) 0.75 686 (78.2) 283 (78.0) 0.92
Coronary artery disease 59 (4.8) 8 (5.6) 0.65 37 (4.2) 22 (6.3) 0.11 37 (4.2) 22 (6.1) 0.17
Smoking 546 (44.0) 65 (45.8) 0.69 407 (45.6) 139 (39.9) 0.07 404 (46.1) 142 (39.1) 0.02
Index event 0.01 0.18 0.05
  Ischemic stroke 1,175 (94.8) 142 (100.0) 850 (95.3) 325 (93.4) 838 (95.6) 337 (92.8)
  Transient ischemic attack 65 (5.2) 0 (0.0) 42 (4.7) 23 (6.6) 39 (4.5) 26 (7.2)
Baseline NIHSS 1 (0–3) 3 (1-5) <0.01 1 (0–3) 2 (1–4) <0.01 1 (0–3) 2 (1–4) <0.01
Baseline MMSE 26 (21–28) - - 26 (23–29) 24 (17–27) <0.01 26 (23–29) 24 (17–27) <0.01
   24 or less 492 (39.7) - 313 (35.1) 179 (51.4) <0.01 303 (34.6) 189 (52.1) <0.01
    >24 748 (60.3) - 579 (64.9) 169 (48.6) 574 (65.4) 174 (47.9)
Baseline MoCA 20 (14–24) - - 20 (16–24) 17 (10–22) <0.01 20 (16–24) 17 (10–22) <0.01
Treatment
   Cilostazol 618 (49.8) 71 (50.0) 0.97 451 (50.6) 167 (48.0) 0.42 447 (51.0) 171 (47.1) 0.22
   Probucol 622 (50.2) 69 (48.6) 0.72 459 (51.5) 163 (46.8) 0.14 452 (51.5) 170 (46.8) 0.13
SBP (mm Hg) 135.4±18.4 133.7±19.1 0.30 135.4±18.6 135.5±17.8 0.96 135.3±18.7 135.6±17.6 0.79
DBP (mm Hg) 80.1±11.8 80.9±12.2 0.43 80.1±11.8 80.2±11.8 0.88 80.1±11.9 80.2±11.6 0.85
BP readings 7 (4–13) 10 (3–18) 0.01 9 (6–13) 2 (1–4) <0.01 9 (6–13) 2 (1–4) <0.01
Follow-up periods (yr) 1.9 (1.0–3.0) 2.7 (0.6–4.5) <0.01 2.1 (1.3–3.0) 0.5 (0.1–1.1) <0.01 2.1 (1.3–3.0) 0.6 (0.1–1.1) <0.01
Severe WMH 324 (27.1) 30 (22.1) 0.21 210 (24.5) 114 (33.5) <0.01 206 (24.4) 118 (33.2) <0.01
Outcome events
  Recurrent stroke† 102 (8.2) 9 (6.3) 0.43 44 (4.9) 58 (16.7) <0.01 41 (4.7) 61 (16.8) <0.01
  Ischemic 80 (6.5) 8 (5.6) 0.71 31 (3.5) 49 (14.1) <0.01 30 (3.4) 50 (13.8) <0.01
  Hemorrhagic 23 (1.9) 1 (0.7) 0.50 14 (1.6) 9 (2.6) 0.23 12 (1.4) 11 (3.0) 0.048
  Myocardial infarction 8 (0.7) 1 (0.7) 0.99 3 (0.3) 5 (1.4) 0.04 3 (0.3) 5 (1.4) 0.04
  Death 39 (3.2) 9 (6.3) 0.08 17 (1.9) 22 (6.3) <0.01 17 (1.9) 22 (6.1) <0.01
Values are presented as mean±standard deviation, number (%), or median (interquartile range). Severe white matter hyperintensities were defined as Fazekas 
grade 3.
PICASSO-COG, PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage for reducing COGnitive decline; MMSE, 
Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment; NIHSS, National Institutes of Health Stroke Scale; SBP, systolic blood pressure; DBP, 
diastolic blood pressure; BP, blood pressure; WMH, white matter hyperintensity.
*Prior to randomization; †One subject had both ischemic and hemorrhagic stroke and was counted as a duplicate.
Vol. 23 / No. 1 / January 2021
https://doi.org/10.5853//jos.2020.03650 http://j-stroke.org 3
Supplementary Table 2. Baseline characteristics of the study subjects 
Characteristic
Antiplatelet treatment Lipid-lowering treatment
Cilostazol (n=451) Aspirin (n=441) Probucol (n=459) No probucol (n=433)
Age (yr) 65.0±10.8 64.8±10.8 64.7±10.8 65.2±10.8
Male sex  283 (62.7) 282 (63.9) 290 (63.2) 275 (63.5)
Education (yr) 9 (6–12) 9 (6–12) 9 (6–12) 9 (6–12)
Entry event  
     Ischemic stroke 432 (95.8) 418 (94.8) 441 (96.1) 409 (94.5)
     Transient ischemic attack 19 (4.2) 23 (5.2) 18 (3.9) 24 (5.5)
Index of high risk of ICH
     Prior history of ICH 69 (15.3) 76 (17.2) 72 (15.7) 73 (16.9)
     Imaging findings of ICH without clinical history 83 (18.4) 77 (17.5) 87 (18.9) 73 (16.9)
     Multiple microbleeds (≥2) 299 (66.3) 288 (65.3) 300 (65.4) 287 (66.3)
Time-to-randomization since entry event (day) 18 (9–41) 18 (9–42) 18 (9–43) 18 (8–41)
     ≤10 130 (28.8) 132 (29.9) 128 (27.9) 134 (30.9)
     11–30 177 (39.2) 173 (39.2) 180 (39.2) 170 (39.3)
     31–90 93 (20.6) 93 (21.1) 95 (20.7) 91 (21.0)
     >90 51 (11.3) 43 (9.8) 56 (12.2) 38 (8.8)
Baseline NIHSS 1 (0–3) 1 (0–3) 1 (0–3) 1 (0–3)
Baseline MMSE 26 (22–28) 27 (23–29) 26 (22–28) 26 (23–29)
     Baseline MMSE ≤24 173 (38.4) 140 (31.7) 160 (34.9) 153 (35.3)
Baseline MoCA 20 (15–24) 21 (16–24) 20 (15.5–24) 21 (16–24)
Time-to-baseline MMSE since entry event (day) 136 (125–148) 135 (127–151) 136 (126–151) 135 (127–148.5)
Risk factors 
     Hypertension 402 (89.1) 394 (89.3) 411 (89.5) 385 (88.9)
     Diabetes mellitus 134 (29.7) 142 (32.2) 136 (29.6) 140 (32.3)
     Dyslipidemia 183 (40.6) 190 (43.1) 206 (44.9) 167 (38.6)
     Current smoking 93 (20.6) 102 (23.1) 103 (22.4) 92 (21.2)
     Coronary artery disease 15 (3.3) 22 (5.0) 22 (4.8) 15 (3.5)
Lipids (mg/dL)
     Total cholesterol 165.7±39.2 169.0±41.1 170.5±40.8 164.0±39.3
     LDL-C 101.0±36.0 102.7±35.4 104.7±36.4 98.7±34.7
     HDL-C 45.2±11.7 45.9±12.1 45.5±12.1 45.5±11.7
Fazekas score for WMH
     0 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
     1 122 (27.1) 141 (32.0) 130 (29.1) 133 (32.4)
     2 194 (43.0) 191 (43.3) 213 (47.6) 172 (41.8)
     3 112 (24.8) 98 (22.2) 104 (23.3) 106 (25.8)
Concomitant therapy
     Aspirin (after randomization) 218 (47.5) 223 (51.5)
     Cilostazol (after randomization) 241 (52.5) 210 (48.5)
     Probucol 241 (53.4) 218 (49.4)
     Other lipid-lowering agents 355 (79.1) 353 (80.2) 360 (78.8) 348 (80.6)
Values are presented as mean±standard deviation, number (%), or median (interquartile range).
ICH, intracerebral hemorrhage; NIHSS, National Institutes of Health Stroke Scale; MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assess-
ment; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; WMH, white matter hyperintensity.
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Supplementary Table 3. MMRM analysis in cilostazol vs. aspirin and probucol vs. no probucol groups
Time point
Cilostazol vs. aspirin Probucol vs. no probucol


















Baseline 24.76±4.48 25.07±4.89 0.81* 18.98±6.16 19.67±6.31 0.31* 24.93±4.73 24.90±4.65 0.57* 19.23±6.15 19.42±6.33 0.01*
1st Follow-up 24.85±4.65 25.10±4.95 <0.01† 19.02±6.37 19.78±6.62 0.045† 25.00±5.03 24.94±4.55 <0.01† 19.44±6.43 19.34±6.58 0.03†
2nd Follow-up 24.61±5.12 25.13±4.92 18.75±6.66 19.91±6.57 24.91±5.03 24.83±5.03 19.31±6.81 19.33±6.46
3rd Follow-up 24.56±5.29 24.82±5.35 19.01±6.80 19.43±6.96 24.81±5.17 24.54±5.48 19.67±6.72 18.69±7.04
4th Follow-up 23.97±5.51 25.15±5.41 18.69±7.34 20.62±6.98 24.41±5.69 24.84±5.17 19.91±7.48 19.36±6.82
Values are presented as mean±standard deviation. P-values for treatment-by-time interaction were not significant in any analysis.
MMRM, maximum likelihood-based mixed effects model with repeated measurements; MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive 
Assessment.
*P-value for MMRM for treatment effect; †P-value for MMRM for the time effect.
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Supplementary Table 4. Subgroup analysis of the cilosatzol/aspirin groups and probucol/no probucol groups
Variable Baseline 1st Follow-up 2nd Follow-up 3rd Follow-up 4th Follow-up
Cilosatzol/aspirin MMSE scores
Baseline MMSE ≤24 (n=313)
Cilostazol (n=173) 20.10±3.56 20.70±4.52 19.84±5.03 19.94±5.26 19.40±5.21
Aspirin (n=140) 19.23±4.41 19.73±5.10 20.01±5.44 19.67±5.90 16.54±6.15
P 0.83* 0.01†
Baseline MMSE >24 (n=579)
Cilostazol (n=278) 27.66±1.65 27.41±2.30 27.28±2.62 27.40±2.64 26.76±3.46
Aspirin (n=301) 27.79±1.65 27.56±2.14 27.34±2.39 27.26±2.67 27.26±2.16
P 0.82* 0.01†
Probucol/no probucol MoCA scores
Diabetes mellitus (n=271)
Probucol (n=135) 18.70±6.29 18.68±6.61 18.17±6.80 18.16±6.85 18.59±8.46
No probucol (n=136) 18.82±6.06 18.71±6.14 18.52±6.00 17.72±6.28 18.05±6.76
P 0.16* 0.18†
No diabetes mellitus (n=606)
Probucol (n=317) 19.45±6.09 19.77±6.34 19.77±6.78 20.19±6.61 20.28±7.22
No probucol (n=289) 19.70±6.45 19.63±6.77 19.72±6.65 19.21±7.40 20.24±6.82
P 0.02* 0.01†
Concomitant lipid-lowering agents (n=699)
Probucol (n=355) 19.46±6.08 19.73±6.28 19.81±6.60 20.06±6.51 20.69±7.19
No probucol (n=344) 19.47±6.35 19.44±6.62 19.59±6.38 19.23±6.70 19.45±6.73
P 0.08* 0.38†
No concomitant lipid-lowering agents (n=175)
Probucol (n=95) 18.35±6.41 18.44±6.94 17.71±7.30 18.58±7.28 17.06±8.23
No probucol (n=80) 19.21±6.34 18.84±6.46 18.30±6.75 16.62±7.95 19.13±7.30
P 0.03* 0.03†
Baseline MMSE ≤24 (n=303)
Probucol (n=155) 12.94±4.90 12.90±5.11 12.60±5.79 13.21±5.82 11.92±6.41
No probucol (n=148) 12.86±5.10 12.78±5.13 12.17±4.89 11.61±5.64 8.55±5.43
P 0.18* <0.01†
Baseline MMSE >24 (n=574)
Probucol (n=297) 22.51±3.69 22.78±4.03 22.75±4.26 23.14±4.10 23.75±4.22
No probucol (n=277) 22.92±3.52 22.82±4.17 22.55±4.05 22.42±4.30 22.07±3.77
P 0.01* 0.88†
Mild to moderate white matter hyperintensities (n=637)
Probucol (n=338) 20.37±5.51 20.75±5.86 20.70±6.10 20.97±5.95 21.42±6.42
No probucol (n=299) 20.48±5.91 20.43±6.15 20.47±5.76 20.16±6.10 20.85±5.28
P <0.01* 0.40†
Severe white matter hyperintensities (n=206)
Probucol (n=102) 15.49±6.58 15.18±6.44 14.69±7.06 15.35±7.41 14.20±8.85
No probucol (n=104) 16.35±6.61 16.03±6.82 15.99±7.24 14.05±7.87 15.30±9.29
P 0.79* 0.01†
Values are presented as mean±standard deviation. Mild to moderate white matter hyperintensities were defined as Fazekas grade 1 or 2, and severe white 
matter hyperintensities as Fazekas grade 3. P-values for treatment by time interactions were not significant for any analysis.
MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment. 
*P-value by MMRM for the treatment effect; †P-value by MMRM for the time effect.
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Supplementary Table 5. Comparisons of MMSE scores between cilostazol and aspirin group according to severity of white matter changes in propensity 
score matched subsets  
MMSE scores
Mild to moderate white matter hyperintensities (n=574) Severe white matter hyperintensities (n=148)
Cilostazol (n=287) Aspirin  (n=287) P Cilostazol (n=74) Aspirin (n=74) P
Baseline 25.85±3.79 25.85±4.25 0.02* 22.66±4.69 22.27±6.01 0.12*
1st Follow-up 26.14±3.59 25.99±4.36 0.26† 21.95±5.36 22.01±5.72 <0.01†
2nd Follow-up 26.08±3.99 25.83±4.05 21.79±5.85 21.74±6.81
3rd Follow-up 26.43±3.30 25.47±4.63 20.03±6.53 21.47±7.16
4th Follow-up 26.30±3.06 25.75±5.18 16.90±6.87 20.73±7.04
Values are presented as mean±standard deviation. The propensity score was calculated using variables, including the participant’s age, sex, duration of educa-
tion, baseline National Institutes of Health Stroke Scale (NIHSS) score, baseline MMSE score, baseline Montreal Cognitive Assessment (MoCA) score, coronary 
artery disease (yes/no), hypertension (yes/no), systolic blood pressure, and pattern of measurement within each white matter hyperintensity. Mild to moderate 
white matter hyperintensities were defined as Fazekas grade 1 or 2, and severe white matter hyperintensities as Fazekas grade 3. P-values for treatment by 
time interactions were not significant for any analysis.
MMSE, Mini-Mental State Examination.
*P-value by MMRM for the treatment effect; †P-value by MMRM for the time effect.
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Supplementary Figure 1. Flow diagram of subject enrollment. PICASSO-COG, PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk 

















24 Without follow-up MMSE
1 Improper cognitive tests
3 Withdrew consent
32 Without follow-up MMSE
2 Improper cognitive tests
0 Withdrew consent
34 Without follow-up MMSE
4 Improper cognitive tests
4 Withdrew consent
23 Without follow-up MMSE
2 Improper cognitive tests
316 Assigned to
aspirin
302 Assigned to
cilostazol
